PURPOSE: A fully scalable and extrusion-free method was developed to prepare rapidly and reproducibly stabilized plasmid lipid particles (SPLP) for nonviral, systemic gene therapy. METHODS: Liposomes encapsulating plasmid DNA were formed instantaneously by mixing lipids dissolved in ethanol with an aqueous solution of DNA in a controlled, stepwise manner. Combining DNA-buffer and lipid-ethanol flow streams in a T-shaped mixing chamber resulted in instantaneous dilution of ethanol below the concentration required to support lipid solubility. The resulting DNA-containing liposomes were further stabilized by a second stepwise dilution. RESULTS: Using this method, monodisperse vesicles were prepared with particle sizes less than 200 nm and DNA encapsulation efficiencies greater than 80%. In mice possessing Neuro 2a tumors, SPLP demonstrated a 13 h circulation half-life in vivo, good tumor accumulation and gene expression profiles similar to SPLP previously prepared by detergent dialysis. Cryo transmission electron microscopy analysis showed that SPLP prepared by stepwise ethanol dilution were a mixed population of unilamellar, bilamellar, and oligolamellar vesicles. Vesicles of similar lipid composition, prepared without DNA, were also <200 nm but were predominantly bilamellar with unusual elongated morphologies, suggesting that the plasmid particle affects the morphology of the encapsulating liposome. A similar approach was used to prepare neutral egg phosphatidylcholine:cholesterol (EPC:Chol) liposomes possessing a pH gradient, which was confirmed by the uptake of the lipophilic cation safranin O. CONCLUSIONS: This new method will enable the scale-up and manufacture of SPLP required for preclinical and clinical studies. Additionally, this method now allows for the acceleration of SPLP formulation development, enabling the rapid development and evaluation of novel carrier systems.
PURPOSE: A fully scalable and extrusion-free method was developed to prepare rapidly and reproducibly stabilized plasmid lipid particles (SPLP) for nonviral, systemic gene therapy. METHODS: Liposomes encapsulating plasmid DNA were formed instantaneously by mixing lipids dissolved in ethanol with an aqueous solution of DNA in a controlled, stepwise manner. Combining DNA-buffer and lipid-ethanol flow streams in a T-shaped mixing chamber resulted in instantaneous dilution of ethanol below the concentration required to support lipid solubility. The resulting DNA-containing liposomes were further stabilized by a second stepwise dilution. RESULTS: Using this method, monodisperse vesicles were prepared with particle sizes less than 200 nm and DNA encapsulation efficiencies greater than 80%. In mice possessing Neuro 2a tumors, SPLP demonstrated a 13 h circulation half-life in vivo, good tumor accumulation and gene expression profiles similar to SPLP previously prepared by detergent dialysis. Cryo transmission electron microscopy analysis showed that SPLP prepared by stepwise ethanol dilution were a mixed population of unilamellar, bilamellar, and oligolamellar vesicles. Vesicles of similar lipid composition, prepared without DNA, were also <200 nm but were predominantly bilamellar with unusual elongated morphologies, suggesting that the plasmid particle affects the morphology of the encapsulating liposome. A similar approach was used to prepare neutral egg phosphatidylcholine:cholesterol (EPC:Chol) liposomes possessing a pH gradient, which was confirmed by the uptake of the lipophilic cation safranin O. CONCLUSIONS: This new method will enable the scale-up and manufacture of SPLP required for preclinical and clinical studies. Additionally, this method now allows for the acceleration of SPLP formulation development, enabling the rapid development and evaluation of novel carrier systems.
Authors: N Maurer; K F Wong; H Stark; L Louie; D McIntosh; T Wong; P Scherrer; S C Semple; P R Cullis Journal: Biophys J Date: 2001-05 Impact factor: 4.033
Authors: J C Stavridis; G Deliconstantinos; M C Psallidopoulos; N A Armenakas; D J Hadjiminas; J Hadjiminas Journal: Exp Cell Res Date: 1986-06 Impact factor: 3.905
Authors: P Tam; M Monck; D Lee; O Ludkovski; E C Leng; K Clow; H Stark; P Scherrer; R W Graham; P R Cullis Journal: Gene Ther Date: 2000-11 Impact factor: 5.250
Authors: A H Sarris; F Hagemeister; J Romaguera; M A Rodriguez; P McLaughlin; A M Tsimberidou; L J Medeiros; B Samuels; O Pate; M Oholendt; H Kantarjian; C Burge; F Cabanillas Journal: Ann Oncol Date: 2000-01 Impact factor: 32.976
Authors: Sherry Y Wu; Lisa N Putral; Mingtao Liang; Hsin-I Chang; Nigel M Davies; Nigel A J McMillan Journal: Pharm Res Date: 2008-11-21 Impact factor: 4.200
Authors: Kevin T Love; Kerry P Mahon; Christopher G Levins; Kathryn A Whitehead; William Querbes; J Robert Dorkin; June Qin; William Cantley; Liu Liang Qin; Timothy Racie; Maria Frank-Kamenetsky; Ka Ning Yip; Rene Alvarez; Dinah W Y Sah; Antonin de Fougerolles; Kevin Fitzgerald; Victor Koteliansky; Akin Akinc; Robert Langer; Daniel G Anderson Journal: Proc Natl Acad Sci U S A Date: 2010-01-11 Impact factor: 11.205
Authors: Torben Gjetting; Thomas Lars Andresen; Camilla Laulund Christensen; Frederik Cramer; Thomas Tuxen Poulsen; Hans Skovgaard Poulsen Journal: Results Pharma Sci Date: 2011-09-03
Authors: Sean C Semple; Akin Akinc; Jianxin Chen; Ammen P Sandhu; Barbara L Mui; Connie K Cho; Dinah W Y Sah; Derrick Stebbing; Erin J Crosley; Ed Yaworski; Ismail M Hafez; J Robert Dorkin; June Qin; Kieu Lam; Kallanthottathil G Rajeev; Kim F Wong; Lloyd B Jeffs; Lubomir Nechev; Merete L Eisenhardt; Muthusamy Jayaraman; Mikameh Kazem; Martin A Maier; Masuna Srinivasulu; Michael J Weinstein; Qingmin Chen; Rene Alvarez; Scott A Barros; Soma De; Sandra K Klimuk; Todd Borland; Verbena Kosovrasti; William L Cantley; Ying K Tam; Muthiah Manoharan; Marco A Ciufolini; Mark A Tracy; Antonin de Fougerolles; Ian MacLachlan; Pieter R Cullis; Thomas D Madden; Michael J Hope Journal: Nat Biotechnol Date: 2010-01-17 Impact factor: 54.908